title: Waldenstrom's macroglobulinemia: is there a place and time for a cease-fire?
authors.forename: Pier Luigi
authors.initials: PL
authors.lastname: Zinzani
authors.forename: Monica
authors.initials: M
authors.lastname: Tani
authors.forename: Lapo
authors.initials: L
authors.lastname: Alinari
authors.forename: Vittorio
authors.initials: V
authors.lastname: Stefoni
authors.forename: Michele
authors.initials: M
authors.lastname: Baccarani
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001761:Bleomycin / Q000627:therapeutic use; D019090:Case Management; D002699:Chlorambucil / Q000627:therapeutic use; D017338:Cladribine / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D005047:Etoposide / Q000627:therapeutic use; D006801:Humans; D007075:Immunoglobulin M / Q000097:blood; D008297:Male; D008875:Middle Aged; D008942:Mitoxantrone / Q000627:therapeutic use; D010956:Plasmapheresis; D011241:Prednisone / Q000627:therapeutic use; D000069283:Rituximab; D012720:Severity of Illness Index; D013792:Thalidomide / Q000627:therapeutic use; D014740:Vidarabine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D014747:Vinblastine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D014750:Vincristine / Q000627:therapeutic use; D000077235:Vinorelbine; D008258:Waldenstrom Macroglobulinemia / Q000188:drug therapy / Q000628:therapy*
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D007075:Immunoglobulin M; D001761:Bleomycin; D002699:Chlorambucil; D017338:Cladribine; D000069283:Rituximab; D013792:Thalidomide; D014750:Vincristine; D014747:Vinblastine; D005047:Etoposide; D004317:Doxorubicin; D003520:Cyclophosphamide; D008942:Mitoxantrone; D014740:Vidarabine; C024352:fludarabine; D000077235:Vinorelbine; D011241:Prednisone